ASX Announcement

Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch

October U.S. sales of 92 Remplir units generate AU$279,000 in monthly revenue

- **Sales of 92 Remplir™ units in October 2026 generated AU$279,000 in revenue, representing an 84% uplift on average monthly sales of 50 units during Q1 FY27.**
- **The groundwork laid to launch Remplir in the U.S. is now translating into tangible revenue as Orthocell's commercial strategy gains traction.**
- **The result reflects growing surgeon adoption, increasing repeat use, a broader base of actively selling distributor representatives and expanded hospital access across key U.S. markets.**
- **October's performance provides encouraging evidence of strengthening U.S. commercial momentum and supports the outlook for continued Remplir revenue growth.**

Perth, Australia; 02 November 2026: Orthocell Limited (ASX: OCC) is pleased to provide an update on U.S. commercial performance for its nerve repair product, Remplir™, following the completion of October 2026 trading. The update is being provided ahead of the Company's Annual General Meeting on 6 November 2026, with standard quarterly reporting to continue thereafter.

Orthocell achieved **U.S. sales of 92 Remplir units in October, generating AU$279,000 in revenue and representing an 84% uplift on the average monthly sales of 50 units during Q1 FY27.**

This represents the strongest month of U.S. sales since launch and reflects growing surgeon adoption, increasing repeat utilisation, an expanding network of actively selling distributor representatives and broader hospital access across key U.S. markets. These results demonstrate progress in converting expanded market access into increased product utilisation and revenue.

Orthocell CEO and MD, Paul Anderson, said: "October represents an important milestone in Orthocell's U.S. commercialisation, with the groundwork laid over the past 12 months now translating into tangible revenue.

The improvement in key commercial indicators demonstrates that Remplir is gaining traction in the U.S. market. While establishing a new medical technology in a large market takes time and sustained effort, our focus remains on accelerating surgeon adoption, expanding hospital access and increasing product utilisation."

Commercial Growth Accelerating

Orthocell has consistently communicated that commercialisation of innovative medical technologies follows a progressive adoption pathway as surgeons gain familiarity with new treatment options and hospital access expands through Value Assessment Committee (VAC) approvals.

October's performance represents a significant uplift in U.S. sales, reflecting progress in converting expanding market access into commercial utilisation. This U.S. progress, combined with regulatory approvals across seven international jurisdictions and established manufacturing capability, provides a foundation for continued commercial growth.

Orthocell will continue to focus on expanding surgeon adoption, strengthening its active distributor network and growing Remplir utilisation across approved markets to support sustainable revenue growth.

Orthocell Chairman John Van Der Wielen commented: "The Board is encouraged by the October sales result and the progress achieved in U.S. commercialisation. Orthocell has invested in the commercial infrastructure required to support Remplir's expansion and is continuing to expand its manufacturing capacity in anticipation of increased demand.
The Board remains confident in the product's significant U.S. market potential and the Company's strategy to translate growing market adoption into long-term commercial success."

Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries	Media enquiries	Investor enquiries
Paul Anderson Orthocell Limited CEO and MD P: +61 8 9360 2888 E: paul.anderson@orthocell.com	**Haley Chartres** **H^CK Director** P: +61 423 139 163 E: haley@hck.digital	**Shaun Duffy** **VECTOR Advisors** P: +61 404 094 384 E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135
Registered Office – Level 2, 161 Campus Drive, Murdoch University, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @Orthocellltd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate, "expect," "intend," "may," "plan," "predict," "project," "target, "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.